SAN DIEGO, Jan. 9, 2018 /PRNewswire/ -- Biocept, Inc.
(NASDAQ: BIOC), a leading commercial provider of liquid biopsy
tests designed to provide physicians with clinically actionable
information to improve the outcomes of patients diagnosed with
cancer, announces that incorporation of the Thermo Fisher
QuantStudio5 (QS5) real-time PCR instrument into the Company's
Target Selector™ ctDNA lung cancer assays improves detection of key
lung cancer mutations. Data from 3,000 samples analyzed using
Biocept's liquid biopsy assays for EGFR, BRAF and KRAS mutations
demonstrated single mutant copy detection on the QS5 platform with
more than 99% sensitivity and more than 99% specificity. The
results will be presented in a poster at the Fifth AACR-IASLC
International Joint Conference: Lung Cancer Translational Science
from the Bench to the Clinic being held January 8-11, 2018 in San Diego.
"These results demonstrate that the high sensitivity of our
Target Selector™ ctDNA assay platform is further improved by the
use of QS5 versus the PCR instrument we previously used," said
Biocept's Senior Vice President and Senior Medical Director
Veena Singh, MD. "The ability
to rapidly and accurately assess the molecular status of a
patient's tumor using a simple blood draw can be a critical factor
in the selection of individualized targeted therapy. Our tests can
further provide for the monitoring of response to therapy over time
without invasive tissue biopsies that can be difficult to perform
in patients diagnosed with cancer."
"We are very pleased to showcase the superb performance of our
Target Selector™ ctDNA assays using the QS5 at this conference
attended by professionals directly involved in the care of patients
with lung cancer," said Biocept's President and CEO Michael Nall. "We believe that these results
further solidify our leadership position in the liquid biopsy
segment and are representative of our actions to build the body of
evidence supporting the analytical performance and clinical utility
of our proprietary liquid biopsy tests."
About the AACR-IASLC International Conference
The Fifth AACR-IASLC International Joint Conference features
translational science that spans from basic research at the bench
to patient care in the clinic. Historically, this conference has
joined a diverse group of attendees (physicians, patient advocates,
and scientists in basic, translational, and clinical lung cancer
research) and provided a venue to discuss recent advances and
establish new collaborations. Sessions range in topics spanning
immunotherapy, molecular targets, genetics, drug resistance,
clinical trials, patient advocacy, and more. The conference is a
dynamic collaboration between the AACR and the IASLC, two
organizations committed to the study of cancer, as well as the many
individuals charged with the study and treatment of this
disease.
About Biocept
Biocept, Inc. is a molecular diagnostics company with
commercialized assays for lung, breast, gastric, colorectal and
prostate cancers, and melanoma. The Company uses its
proprietary liquid biopsy technology to provide physicians with
information for treating and monitoring patients diagnosed with
cancer. The Company's patented Target Selector™ liquid biopsy
technology platform captures and analyzes tumor-associated
molecular markers in both circulating tumor cells (CTCs) and in
plasma (ctDNA). With thousands of tests performed, the
platform has demonstrated the ability to identify cancer mutations
and alterations to inform physicians about a patient's disease and
therapeutic options. For additional information, please visit
www.biocept.com.
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based
upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give
no assurance that such expectations and assumptions will prove to
have been correct. Forward-looking statements are generally
identifiable by the use of words like "may," "will," "should,"
"could," "expect," "anticipate," "estimate," "believe," "intend,"
or "project" or the negative of these words or other variations on
these words or comparable terminology. To the extent that
statements in this release are not strictly historical, including
without limitation statements as to our ability to improve the
diagnosis and treatment of cancer, and our ability to support the
analytical performance and clinical utility of our liquid biopsy
tests , such statements are forward-looking, and are made pursuant
to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. The reader is cautioned not to put undue
reliance on these forward-looking statements, as these statements
are subject to numerous risk factors as set forth in our Securities
and Exchange Commission (SEC) filings. The effects of such risks
and uncertainties could cause actual results to differ materially
from the forward-looking statements contained in this release. We
do not plan to update any such forward-looking statements and
expressly disclaim any duty to update the information contained in
this press release except as required by law. Readers are advised
to review our filings with the SEC, which can be accessed over the
Internet at the SEC's website located at www.sec.gov.
View original content with
multimedia:http://www.prnewswire.com/news-releases/biocept-study-shows-incorporation-of-thermo-fisher-quantstudio-5-pcr-instrument-into-target-selector-platform-improves-sensitivity-and-specificity-in-detection-of-lung-cancer-biomarkers-300579572.html
SOURCE Biocept, Inc.